EXTRANODAL NK/T-CELL LYMPHOMA
Clinical trials for EXTRANODAL NK/T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new EXTRANODAL NK/T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for EXTRANODAL NK/T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo targets Tough-to-Treat lymphoma
Disease control Not yet recruitingThis study tests a combination of two drugs, tislelizumab and zeprumetostat, in people with a rare type of lymphoma (NK/T-cell) that has returned or not responded to prior treatment. About 107 adults will take part to find the best dose and measure how well the drugs shrink tumor…
Matched conditions: EXTRANODAL NK/T-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Rong Tao • Aim: Disease control
Last updated May 26, 2026 08:21 UTC
-
Lower radiation, same hope: new drug combo aims to tame lymphoma with fewer side effects
Disease control Not yet recruitingThis study tests whether adding the drug selinexor to a lower dose of radiation (40 Gy) can work as well as standard high-dose radiation for early-stage NK/T-cell lymphoma, while causing fewer side effects like mouth sores and dry mouth. About 34 adults with untreated stage I-II …
Matched conditions: EXTRANODAL NK/T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Beijing Tongren Hospital • Aim: Disease control
Last updated May 26, 2026 08:12 UTC
-
New combo therapy aims to boost lymphoma remission
Disease control Not yet recruitingThis phase 2 trial tests whether adding golidocitinib to standard chemotherapy and an immunotherapy drug improves outcomes for people with advanced NK/T-cell lymphoma. About 40 adults with newly diagnosed stage III-IV or non-nasal disease will be randomly assigned to receive eith…
Matched conditions: EXTRANODAL NK/T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: WEI XU • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New hope for rare blood cancer: drug combo targets relapsed lymphoma
Disease control Not yet recruitingThis study tests whether adding the drug sugemalimab to standard chemotherapy can help people with a rare type of blood cancer (extranodal NK/T-cell lymphoma) that has returned or stopped responding to previous treatment. About 150 adults will receive either the combination or a …
Matched conditions: EXTRANODAL NK/T-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: CStone Pharmaceuticals • Aim: Disease control
Last updated May 11, 2026 20:52 UTC